{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:53Z","timestamp":1789785353432,"version":"4.0.1"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"4","funder":[{"name":"the National Key Program of Clinical Science","award":["WBYZ2011-873"],"award-info":[{"award-number":["WBYZ2011-873"]}]},{"name":"the CAMS Innovation Fund for Medical Science","award":["2016-I2M-1-008"],"award-info":[{"award-number":["2016-I2M-1-008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2021-0735_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to compare the efficacy, safety and metabolic effects of once-weekly pegylated human growth hormone (PEG-rhGH) with daily rhGH in patients with growth hormone deficiency (GHD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0735_abs_002\">\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>48 patients enrolled in this 12-month single-center, open-label, prospective, randomized controlled trial is allocated to PEG-rhGH 0.12\u00a0mg\/kg\/w and 0.20\u00a0mg\/kg\/w treatment. Besides, the control group allocated 23 patients treated with daily rhGH 0.28\u00a0mg\/kg\/w matched with sex, age, and baseline IGF-1 levels. The primary endpoint included height velocity (HV) and IGF-1 increase at the end of treatment. Other parameters associated with growth, metabolism and safety were also monitored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0735_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In terms of HV increase, the efficacy of PEG-rhGH dosed at 0.12\u00a0mg\/kg\/w and 0.20\u00a0mg\/kg\/w was comparable to that of daily rhGH dosed at 0.28\u00a0mg\/kg\/w after 3, 6 and 12 treatment (p&gt;0.05). IGF-1 concentration and IGF-1 SDS were both elevated significantly at 3, 6 and 12\u00a0months (p=0.000) into normal range following PEG-rhGH treatment. BMI SDS elevated after PEG-rhGH treatment for 3, 6 and 12\u00a0months (p=0.000). HbA1c elevated after 3 and 12\u00a0months (p=0.009) and METS-IR elevated after 6\u00a0months (p=0.019) compared with baseline. The differences of other metabolic indexes (such as blood glucose, blood lipid, etc.) have no statistical significance (p&gt;0.05). No severe adverse event was observed among the three groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0735_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The efficacy and safety were promising and comparable between once-weekly PEG-rhGH and daily rhGH injection within 12\u00a0months. The negative influence on glucose homeostasis needed attention and monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2021-0735","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T15:07:38Z","timestamp":1646406458000},"page":"511-517","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency"],"prefix":"10.1515","volume":"35","author":[{"given":"Hanze","family":"Du","sequence":"first","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Centre, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danning","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Centre, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China"},{"name":"Eight-year Program of Clinical Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Affiliated Hospital of Jining Medical University , Jining , Shandong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Bai","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology , Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Luo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology , Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Centre, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Centre, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Centre, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"2023033123535384882_j_jpem-2021-0735_ref_001","doi-asserted-by":"crossref","unstructured":"Chamberlain Shea, H, Levy, RA. Transition care of patients with growth hormone deficiency from pediatric endocrinologists to adult endocrinologists. Endocr Pract 2012;18:256\u201368.","DOI":"10.4158\/EP11168.RA"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_002","unstructured":"Desrosiers, P, O\u2019Brien, F, Blethen, S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005;2:327\u201331."},{"key":"2023033123535384882_j_jpem-2021-0735_ref_003","doi-asserted-by":"crossref","unstructured":"Kapoor, RR, Burke, SA, Sparrow, SE, Hughes, IA, Dunger, DB, Ong, KK, et al.. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93:147\u20138.","DOI":"10.1136\/adc.2006.114249"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_004","doi-asserted-by":"crossref","unstructured":"Fisher, BG, Acerini, CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr 2013;79:189\u201396.","DOI":"10.1159\/000350251"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_005","doi-asserted-by":"crossref","unstructured":"Rosenfeld, RG, Bakker, B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14:143\u201354.","DOI":"10.4158\/EP.14.2.143"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_006","unstructured":"Christiansen, JS, Backeljauw, PF, Bidlingmaier, M, Biller, BM, Boguszewski, MC, Casanueva, FF, et al.. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol 2016;174:C1\u20138."},{"key":"2023033123535384882_j_jpem-2021-0735_ref_007","doi-asserted-by":"crossref","unstructured":"Cutfield, WS, Derraik, JG, Gunn, AJ, Reid, K, Delany, T, Robinson, E, et al.. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011;6:e16223.","DOI":"10.1371\/journal.pone.0016223"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_008","doi-asserted-by":"crossref","unstructured":"Guyda, HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307\u201316.","DOI":"10.1210\/jcem.84.12.6189"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_009","doi-asserted-by":"crossref","unstructured":"Hoybye, C, Cohen, P, Hoffman, AR, Ross, R, Biller, BM, Christiansen, JS. Status of long-acting-growth hormone preparations--2015. Growth Hormone IGF Res 2015;25:201\u20136.","DOI":"10.1016\/j.ghir.2015.07.004"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_010","doi-asserted-by":"crossref","unstructured":"Hou, L, Chen, ZH, Liu, D, Cheng, YG, Luo, XP. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Dev Ther 2016;10:13\u201321.","DOI":"10.2147\/DDDT.S93183"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_011","doi-asserted-by":"crossref","unstructured":"Rasmussen, MH, Bysted, BV, Anderson, TW, Klitgaard, T, Madsen, J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab 2010;95:3411\u20137.","DOI":"10.1210\/jc.2009-2813"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_012","doi-asserted-by":"crossref","unstructured":"Xu, S, Gu, X, Pan, H, Zhu, H, Gong, F, Li, Y, et al.. Reference ranges for serum IGF-1 and IGFBP-3 levels in Chinese children during childhood and adolescence. Endocr J 2010;57:221\u20138.","DOI":"10.1507\/endocrj.K09E-200"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_013","doi-asserted-by":"crossref","unstructured":"Simental-Mend\u00eda, LE, Rodr\u00edguez-Mor\u00e1n, M, Guerrero-Romero, F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 2008;6:299\u2013304.","DOI":"10.1089\/met.2008.0034"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_014","doi-asserted-by":"crossref","unstructured":"Abbasi, F, Reaven, GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides \u00d7 glucose versus triglyceride\/high-density lipoprotein cholesterol. Metabolism 2011;60:1673\u20136.","DOI":"10.1016\/j.metabol.2011.04.006"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_015","doi-asserted-by":"crossref","unstructured":"Bello-Chavolla, OY, Almeda-Valdes, P, Gomez-Velasco, D, Viveros-Ruiz, T, Cruz-Bautista, I, Romo-Romo, A, et al.. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol 2018;178:533\u201344.","DOI":"10.1530\/EJE-17-0883"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_016","doi-asserted-by":"crossref","unstructured":"Reiter, EO, Price, DA, Wilton, P, Albertsson-Wikland, K, Ranke, MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047\u201354.","DOI":"10.1210\/jc.2005-2284"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_017","doi-asserted-by":"crossref","unstructured":"Jorgensen, JO, Pedersen, SA, Thuesen, L, Jorgensen, J, Ingemann-Hansen, T, Skakkebaek, NE, et al.. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221\u20135.","DOI":"10.1016\/S0140-6736(89)92328-3"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_018","doi-asserted-by":"crossref","unstructured":"van der Klaauw, AA, Romijn, JA, Biermasz, NR, Smit, JW, van Doorn, J, Dekkers, OM, et al.. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006;155:701\u20138.","DOI":"10.1530\/eje.1.02283"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_019","doi-asserted-by":"crossref","unstructured":"Luo, X, Hou, L, Liang, L, Dong, G, Shen, S, Zhao, Z, et al.. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 2017;177:195\u2013205.","DOI":"10.1530\/EJE-16-0905"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_020","doi-asserted-by":"crossref","unstructured":"Laursen, T, Gravholt, CH, Heickendorff, L, Drustrup, J, Kappelgaard, AM, Jorgensen, JO, et al.. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 2001;86:1222\u20138.","DOI":"10.1210\/jc.86.3.1222"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_021","doi-asserted-by":"crossref","unstructured":"Zelinska, N, Iotova, V, Skorodok, J, Malievsky, O, Peterkova, V, Samsonova, L, et al.. Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab 2017;102:1578\u201387.","DOI":"10.1210\/jc.2016-3547"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_022","doi-asserted-by":"crossref","unstructured":"Colao, A, Vitale, G, Pivonello, R, Ciccarelli, A, Di Somma, C, Lombardi, G. The heart: an end-organ of GH action. Eur J Endocrinol 2004;151:S93\u2013101.","DOI":"10.1530\/eje.0.151s093"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_023","doi-asserted-by":"crossref","unstructured":"Cohen, P, Clemmons, DR, Rosenfeld, RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Hormone IGF Res 2000;10:297\u2013305.","DOI":"10.1054\/ghir.2000.0171"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_024","doi-asserted-by":"crossref","unstructured":"de Schepper, J, Rasmussen, MH, Gucev, Z, Eliakim, A, Battelino, T. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur J Endocrinol 2011;165:401\u20139.","DOI":"10.1530\/EJE-11-0536"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_025","doi-asserted-by":"crossref","unstructured":"Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BM, Boguszewski, M, Burman, P, et al.. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 2016;174:1\u20139.","DOI":"10.1530\/EJE-15-0873"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_026","doi-asserted-by":"crossref","unstructured":"Touraine, P, D\u2019Souza, GA, Kourides, I, Abs, R, Barclay, P, Xie, R, et al.. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 2009;161:533\u201340.","DOI":"10.1530\/EJE-09-0422"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_027","doi-asserted-by":"crossref","unstructured":"Silverman, BL, Blethen, SL, Reiter, EO, Attie, KM, Neuwirth, RB, Ford, KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metabol 2002;15:715\u201322.","DOI":"10.1515\/JPEM.2002.15.S2.715"},{"key":"2023033123535384882_j_jpem-2021-0735_ref_028","doi-asserted-by":"crossref","unstructured":"Khadilkar, V, Radjuk, KA, Bolshova, E, Khadgawat, R, El Kholy, M, Desai, M, et al.. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab 2014;99:126\u201332.","DOI":"10.1210\/jc.2013-2502"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0735\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T13:13:55Z","timestamp":1680354835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0735\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,16]]},"published-print":{"date-parts":[[2022,4,26]]}},"alternative-id":["10.1515\/jpem-2021-0735"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2021-0735","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}